These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2581332)

  • 41. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
    Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
    Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preservation of platelet function in cryopreserved platelet concentrates with prostacyclin.
    Johnson EJ; Mackie IJ; Machin SJ; Brozović B
    Clin Lab Haematol; 1984; 6(2):141-4. PubMed ID: 6207975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hemodynamic effects of prostacyclin infusions in healthy volunteers.
    Wollersheim H; Thien T
    Angiology; 1988 Mar; 39(3 Pt 1):227-33. PubMed ID: 2965535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet antiaggregatory substances inhibit arachidonic acid induced coronary constriction.
    Ioannou P; Talesnik J
    Can J Physiol Pharmacol; 1986 Apr; 64(4):398-405. PubMed ID: 2425912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW; Maderna P; Accomazzo MR; Nicosia S; Tremoli E
    Biochem Pharmacol; 1989 Jan; 38(1):39-45. PubMed ID: 2462881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.
    Schrör K; Darius H; Matzky R; Ohlendorf R
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Jun; 316(3):252-5. PubMed ID: 6166877
    [No Abstract]   [Full Text] [Related]  

  • 47. Platelet hyperaggregability occurring during prolonged continuous intravenous infusions of prostacyclin analogue ZK 36374.
    Yardumian DA; Mackie IJ; Bull H; Goldstone AH; Machin SJ
    Br J Haematol; 1985 May; 60(1):109-16. PubMed ID: 2408653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of intravenous infusion of prostacyclin (PGI2) in man.
    O'Grady J; Warrington S; Moti MJ; Bunting S; Flower R; Fowle AS; Higgs EA; Moncada S
    Prostaglandins; 1980 Feb; 19(2):319-32. PubMed ID: 6992228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
    Kobzar G; Mardla V; Järving I; Samel N
    Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size.
    Smith EF; Gallenkämper W; Beckmann R; Thomsen T; Mannesmann G; Schrör K
    Cardiovasc Res; 1984 Mar; 18(3):163-73. PubMed ID: 6200229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of dazoxiben, an inhibitor of thromboxane synthetase, on forearm vasoconstriction in response to cold stimulation, and on human blood vessel prostacyclin production.
    Cowley AJ; Jones EW; Hanley SP
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):107S-112S. PubMed ID: 6337600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers.
    Virgolini I; Fitscha P; Sinzinger H; Barth H
    Eur J Clin Pharmacol; 1990; 38(4):347-50. PubMed ID: 2111774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet function.
    Rao GH; Reddy KR; Hagert K; White JG
    Prostaglandins Med; 1980 Apr; 4(4):263-73. PubMed ID: 6994159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinetics of thrombin-induced release and activation of platelet factor V.
    Baruch D; Hemker HC; Lindhout T
    Eur J Biochem; 1986 Jan; 154(1):213-8. PubMed ID: 2417835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A stable non-prostaglandin inhibitor of platelet aggregation in human aorta intima extracts.
    Du P Heyns A; Badenhorst CJ; Retief FP
    S Afr Med J; 1979 Jun; 55(23):908-10. PubMed ID: 472926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of the stable prostacyclin analogue ZK 36374 on experimental coronary thrombosis in the pig.
    van der Giessen WJ; Mooi WJ; Rutteman AM; Berk L; Verdouw PD
    Thromb Res; 1984 Oct; 36(1):45-51. PubMed ID: 6209820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction.
    Jakubowski JA; Adler B; Thompson CB; Valeri CR; Deykin D
    J Lab Clin Med; 1985 Feb; 105(2):271-6. PubMed ID: 3882862
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice.
    Costantini V; Fuschiotti P; Giampietri A; Allegrucci M; Agnelli G; Nenci GG; Fioretti MC
    Prostaglandins; 1990 Jun; 39(6):581-99. PubMed ID: 1695382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis.
    Belch JJ; O'Dowd A; Forbes CD; Sturrock RD
    Br J Rheumatol; 1985 Nov; 24(4):346-50. PubMed ID: 2415199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
    Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B
    Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.